onPoint Oncology, LLC – Trademark Portfolio

Entity Type: 16

onPoint Oncology, LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 3 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ONPOINT and FOCALPOINT. The owner is based in Hudson, OH.

3006 Pine Trails Circle

Hudson, OH 44236

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

onPoint Oncology, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (3 filings)

Advertising; business management; business administration; office functions

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does onPoint Oncology, LLC have?

onPoint Oncology, LLC has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 cancelled.

What trademark classes does onPoint Oncology, LLC file in?

onPoint Oncology, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 44 (Medical Services). Class 35 covers advertising; business management; business administration; office functions.

What are onPoint Oncology, LLC's most well-known trademarks?

onPoint Oncology, LLC's registered trademark portfolio includes well-known marks such as ONPOINT and FOCALPOINT. These are among 2 currently registered trademarks in the portfolio.

What is onPoint Oncology, LLC's trademark registration success rate?

onPoint Oncology, LLC has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.